Prognostic biomarkers of renal cell carcinoma: Recent advances

Indian Journal of Urology

Volumn 24, Issue 1, 2008, Pages 10-15

  Kitamura, Hiroshi ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Prognosis; Renal cell carcinoma

Indexed keywords

EID: 38349139744     PISSN: 09701591     EISSN: None     Source Type: Journal    
DOI: 10.4103/0970-1591.38596     Document Type: Article

References (40)

1. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:1691-6.
2. Lohse CM, Cheville JC. Areview of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 2005;25:433-64.
3. Lain JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-8.
4. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell carcinoma. J Urol 2007;177:1269-72.
5. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
6. Generali D, Berruti A Brizzi MP, Campo L. Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006;12:4562-8.
7. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11:1129-35.
8. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
9. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997;57:2827-31.
10. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL)tumour suppressor by mRNA differential expression profiling. Oncogene 2000;19:6297-305.
11. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IXis an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
12. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yi H, et al. Using protein expression to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464-71.
13. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yi H, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173:1496-501.
14. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
15. Gilbert SM, Whitson JM Mansukhani M, Buttyan R, Benson MC, Olsson CA, et al. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 2006;67:942-5.
16. Uemura H, Fujimoto K, Tanaka M, Yishikawa M, Hirao Y, Uejima S, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006;12:1768-75.
17. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, Weijer KD, Mulders PF, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007;30:116-22.
18. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 2006;24:e20-2.
19. Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, et al. Expression of vascular endothelial growth factor in renal cell carcinoma. Virchows Arch 2000;436:351-6.
20. Rini Bl, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
21. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13:1098-106.
22. Edgren M, Lennernäs B, Larsson A, Kälkner KM. Angiogenic factors: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res 2001;21:1423-9.
23. Beecken WD, Bentas W, Glienke W, Linneweber J, Jonas D, Binder J. Serum angiogenic activity: Diagnostic relevance in renal cell carcinoma. Eur Urol 2002;42:364-9.
24. Minardi D, Lucarini G, Mazzucchlli R, Milanese G, Natali D, Galosi AB, et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol 2005;174:1208-12.
25. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. Serum levels of vascular endothelial growth tactor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51:168-74.
26. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
27. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-88.
28. Kempkensteffen C, Hinz S, Christoph F, Köllermann J, Krause H, Schrader M, et al. Expression parameters of the inhibitors of apoptosis cIAP1 and CIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer 2006;120:1081-6.
29. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Human Pathol 2004;35:1022-8.
30. Parker AS, Kosari E Lohse CM, Thompson RH, Kwon ED, Murphy L, et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006;107:37-45.
31. Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: associated with pathologic features and clinical outcome. Urology 2007;69:34-7.
32. Kitamura H, Honma I, Torigoe T, Hariu H, Asanuma H, Hirohashi Y, et al. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. Urology 2007;70:38-42.
33. Mizutani Y, Nakanishi H, Yamamoto K, Ii YN, Matsubara H, Mikami K, et al. Downregulation of smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005;23:448-54.
34. Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, et al. B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology 2005;66:10-4.
35. Cózar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, et al. Analysis of NKcells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 2005;54:858-66.
36. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24: 1997-2005.
37. + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13: 2075-81.
38. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci USA 2006;103:10391-6.
39. Jiang Z, Chu FG, Woda BA, Rock KL, Liu Q, Hsieh CC, et al. Analysis of RNA-binding protein LMP3 to predict metastasis and prognosis of renal-cell carcinoma: Aretrospective study. Lancet Oncol 2006;7:556-64.
40. Yio M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H, et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 2005;205:377-87.